Literature DB >> 24695327

Therapeutics: Negative feedback.

Elie Dolgin1.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24695327     DOI: 10.1038/508S10a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

Review 1.  Can repetitive transcranial magnetic stimulation be considered effective treatment option for negative symptoms of schizophrenia?

Authors:  Radovan Prikryl; Hana Prikrylova Kucerova
Journal:  J ECT       Date:  2013-03       Impact factor: 3.635

2.  Safety and proof of principle study of cerebellar vermal theta burst stimulation in refractory schizophrenia.

Authors:  Asli Demirtas-Tatlidede; Catarina Freitas; Jennifer R Cromer; Laura Safar; Dost Ongur; William S Stone; Larry J Seidman; Jeremy D Schmahmann; Alvaro Pascual-Leone
Journal:  Schizophr Res       Date:  2010-12       Impact factor: 4.939

3.  Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Robert W Buchanan; Josette G Harris; James M Gold; Lynn Johnson; Diana Allensworth; Alejandrina Guzman-Bonilla; Bettye Clement; M Patricia Ball; Jay Kutnick; Vicki Pender; Laura F Martin; Karen E Stevens; Brandie D Wagner; Gary O Zerbe; Ferenc Soti; William R Kem
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

Review 4.  Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions.

Authors:  Ori Elis; Janelle M Caponigro; Ann M Kring
Journal:  Clin Psychol Rev       Date:  2013-07-16

5.  A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

Authors:  Jeffrey A Lieberman; Geoffrey Dunbar; Anthony C Segreti; Ragy R Girgis; Frances Seoane; Jessica S Beaver; Naihua Duan; David A Hosford
Journal:  Neuropsychopharmacology       Date:  2012-12-18       Impact factor: 7.853

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.